Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

• Main Authors: Yulan Qi (Author), Gina Patel (Author), Joshua Henshaw (Author), Soumi Gupta (Author), Joy Olbertz (Author), Kevin Larimore (Author), Cary O. Harding (Author), Markus Merilainen (Author), Roberto Zori (Author), Nicola Longo (Author), Barbara K. Burton (Author), Mingjin Li (Author), Zhonghua Gu (Author), Stephen J. Zoog (Author), Haoling H. Weng (Author), Becky Schweighardt (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Phenylketonuria (PKU), a deficiency in the activity of the enzyme phenylalanine hydroxylase, leads to toxic levels of phenylalanine (Phe) in the blood and brain. Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjugated with polyethylene glycol) is approved to manag...